Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
biote
NasdaqGM:BTMD Community
Create a narrative
biote
Popular
Undervalued
Overvalued
biote
WA
Analyst Price Target
Consensus Narrative from 6 Analysts
Expanding Treatment Options And Software Enhancements Will Increase Patient Base And Procedure Volumes
Key Takeaways Expansion into new markets and software enhancement are poised to increase patient base and procedure volumes, driving revenue growth. Integration with Asteria Health and improved supply chain efficiencies are expected to enhance cost efficiencies and net margins.
View narrative
US$9.87
FV
53.6% undervalued
intrinsic discount
16.94%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
18 days ago
author updated this narrative
Your Valuation for
BTMD
biote
Your Fair Value
US$
Current Price
US$4.58
14.5% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-3m
373m
2015
2018
2021
2024
2025
2027
2030
Revenue US$373.3m
Earnings US$13.9m
Advanced
Set as Fair Value